The ongoing novel coronavirus disease (COVID-19) pandemic makes us painfully perceive that our bullet shells are blank so far for fighting against severe human coronavirus (HCoV). In spite of vast research work, it is crystal clear that the evident does not warrant the commercial blossoming of anti-HCoV drugs. In this circumstance, drug repurposing and/or screening of databases are the only fastest option. This study is an initiative to recapitulate the medicinal chemistry of severe acute respiratory syndrome (SARS)-CoV-2 (SARS-CoV-2). The aim is to present an exquisite delineation of the current research from the perspective of a medicinal chemist to allow the rapid development of anti-SARS-CoV-2 agents.

正在进行中的新型冠状病毒病（COVID-19）大流行使我们痛苦地意识到，到目前为止，我们的子弹壳还没有被用来对抗严重的人类冠状病毒（HCoV）。尽管进行了大量的研究工作，但显而易见的是，这一证据并不能保证抗HCoV药物的商业化应用。在这种情况下，重新使用药物和/或筛选数据库是唯一最快的选择。这项研究旨在概述严重急性呼吸综合征（SARS）-CoV-2（SARS-CoV-2）的药物化学作用。目的是从药物化学家的角度提出当前研究的精确描述，以允许快速开发抗SARS-CoV-2药物。